

In the Specification

Please replace the CROSS-REFERENCE TO RELATED APPLICATIONS, first added in applicants' preliminary amendment, with the following amended section:

CROSS-REFERENCE TO RELATED APPLICATIONS

This is the U.S. national stage of International Application No. PCT/EP2003/012889, **which claims the benefit of European patent application no. 03000921.1, filed January 16, 2003.**

Please replace the first full paragraph on page 3, lines 2 – 8, with the following amended paragraph:

Further, the Applicant found that ~~most of the~~ **representative** substituted ~~2-aminoacetamides~~ **2-aminoacetamide** compounds disclosed in WO99/26614 are not effective antimigraine agents and that therefore their usefulness for the treatment of migraine and, generally speaking, of diseases and conditions mediated by sodium ion influx cannot be reasonably predicted in view of their having been recognised as blockers of sodium channels.

Please replace the third full paragraph on page 3 with the following amended paragraph:

The main object of the present invention is to disclose and provide a rapid and highly effective method for treating primary headache disorders including migraine, such as tension type headache, transformed migraine or evolutive headache and cluster headache, as well as secondary headache disorders such as the ones deriving from infection, metabolic disorders, or other systemic illnesses and other acute headaches, in a manner which provides a highly effective treatment with virtually no adverse side effects or lingering after effects (such as drowsiness, grogginess, disorientation, nausea, or the like), thereby allowing the patient to be ready and able to drive, work, or carry out any other normal activity within an hour after ~~that~~ such treatment is commenced.

Please replace the first paragraph on page 12, lines 1 – 6, with the following amended paragraph:

Besides, the use and method of the invention ~~did not show,~~
~~virtually, any~~ should show fewer adverse side effects or lingering
after effects (such as drowsiness, grogginess, disorientation,
nausea, or other such problems), thereby allowing the patient to be
ready and able to drive, work, or carry out any other normal
activity within an hour after that such treatment is commenced.